A revenue-generating, small-cap Canadian pharmaceutical company
Revenue Projected at $150,000,000 by 2025
Message: VIDEO – Valeo Pharma Obtains Public Reimbursement For Asthma Drugs In Quebec and Nova Scotia, Another Step Closer to 2025 Revenue Target of $160M
Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
VIDEO – Valeo Pharma Obtains Public Reimbursement For Asthma Drugs In Quebec and Nova Scotia, Another Step Closer to 2025 Revenue Target of $160M
Valeo Pharma is already a successful, revenue-generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
Q3 Highlights:
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
Record 9 months revenues at $10.2 million , up 94%
Public reimbursement now includes Alberta , Quebec and Nova Scotia , representing approximately 37% of the Canadian population.
More than 90% private insurance coverage across Canada
Frederic Fasano, Valeo's President and Chief Operating Officer commented,
"We are pleased to be reporting today the addition of Quebec and Nova Scotia to join Alberta on the list of provincial public coverage secured for both asthma medications. Public Reimbursement access makes a meaningful impact for asthma patients left with no coverage so far, and also simplify health care providers procedures to provide access of both medications to their patients. Enerzair and Atectura are innovative asthma therapies that are helping make asthma control a more attainable goal for Canadians asthma patients".